Skip to main content

Table 3 Classification base on the two-year PFS and the AUC value using the clearance of HE4 and CA125

From: Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer

 

Two-year PFS

Sensitivity

Specificity

PPV

NPV

Accuracy

P-value

AUC

Yes

No

 

HE4 clearance

HE4 non-clearance

       

1 cycle

45/59 (76.3%)

14/30 (46.7%)

46.7%

76.3%

50.0%

73.8%

66.3%

0.078

0.615

3 cycle

50/59 (84.7%)

17/30 (56.7%)

56.7%

84.7%

65.4%

79.4%

75.3%

0.001

0.707

6 cycle

51/59 (86.4%)

14/30 (46.7%)

46.7%

86.4%

63.6%

76.1%

73.0%

0.011

0.666

 

CA125 clearance

CA125 non-clearance

       

1 cycle

43/59 (72.9%)

17/30 (56.7%)

56.7%

72.9%

51.5%

76.8%

67.4%

0.023

0.648

3 cycle

56/59 (94.9%)

7/30 (23.3%)

23.3%

94.9%

70.0%

70.9%

70.8%

0.161

0.591

6 cycle

57/59 (96.6%)

7/30 (23.3%)

23.3%

96.9%

77.8%

71.3%

71.9%

0.126

0.600

 

HE4 or CA125 clearance

Both HE4 and CA125 non-clearance

      

3 cycle of HE4 or 1 cycle of CA125

37/59 (62.7%)

25/30 (83.3%)

83.3%

62.7%

53.2%

88.1%

69.7%

0.000

0.730

 

Both HE4 and CA125 clearance

HE4 or CA125 non-clearance

       

3 cycle of HE4 and 1 cycle of CA125

56/59 (94.9)

9/30 (30.0%)

30.0%

94.9%

75.0%

72.7%

73.0%

0.056

0.625